Culver City biotech firm NantKwest generated high hopes when it launched an initial public offering last July, but things have gotten off to a rocky start.

The company is set to release revised financial results for the second and third quarters of 2015 reveal the firm has fallen short of expectations since it went public. Its shares have already fallen by about two-thirds from its July initial public offering price of $25, and now the company has been forced to release new financial results due to internal gaffes.

The Wall Street Journal reported Monday that the company, in a statement, attributed its accounting errors to “inadequate staffing levels, resulting in insufficient time spent on review and approval of certain information used to prepare our financial statements.”

NantKwest also said the errors related to “certain stock-based awards” to Chairman and Chief Executive Patrick Soon-Shiong, as well as spending on improvements to its leased facility space.